Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0557 for Cognitive Impairment in Schizophrenia
NCT00482430Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0557 in schizophrenia (2 arms), sponsored by Merck & Co. Primary endpoints: Mean change from baseline on a sequence of cognitive tests at 4 weeks and MK0557 generally well tolerated at 4 weeks. Started Sep 2007; status: completed.
02
Drugs
MK-0557
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00482430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482430.